BCRX BIOCRYST PHARMACEUTICALS INC
FollowStock (common), issuer CIK 882796
Filings received so far for Q3 2026: 5 13F filers report a position in BCRX shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
No 13D or 13G on this security in the data. Structured 13D/G data starts 2024-12-18.
Insider trades
No Form 4 transaction on this security in the data.
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
| Holder | Shares | Value | % of portfolio | Change | Source |
|---|---|---|---|---|---|
| DOLIVER ADVISORS, LP | 304,328 | $2.54M | 0.56% | -70,000 | 13F-HRTimeline |
| Councilor Wealth, LLC | 58,774 | $490K | 0.2% | +28,774 | 13F-HRTimeline |
| Farther Finance Advisors, LLC | 6,138 | $51.1K | <0.01% | -413 | 13F-HRTimeline |
| GAMMA Investing LLC | 1,290 | $10.7K | <0.01% | +61 | 13F-HRTimeline |
| Versant Capital Management, Inc | 399 | $3.32K | <0.01% | -1,604 | 13F-HRTimeline |